Frontlight ResearchEarly access
CompletedNo phase
Efficacy and Safety of 14-Day Vonoprazan-Based Dual Therapy Versus Quadruple Therapy for Helicobacter Pylori Eradication: A Multicentre, Non-Inferiority Randomized Controlled Trial
Key facts
- Who runs it
- Yanqing Li
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 372 people enrolled
- Started
- 20 Sept 2025
- Ended
- 30 Jun 2026
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- 14-day vonoprazan-amoxicillin dual therapy
- 14-day vonoprazan-amoxicillin-levofloxacin-bismuth quadruple therapy
- 14-day vonoprazan-amoxicillin-clarithromycin-bismuth quadruple therapy
- Record updated
- 23 October 2026
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Aged 18-70 years, male or female
- Patients with H. pylori infection (positive 13C-urea breath test, together with at least one positive result from the following three tests: (a) stool H. pylori antigen test; (b) rapid urease test; (c) histopathological examination of gastric mucosal biopsy tissue)
- No prior Helicobacter pylori eradication therapy
Who cannot take part
- Presence of other risk-increasing behaviours such as alcohol abuse or illicit drug use
- Severe underlying conditions, such as hepatic insufficiency, renal insufficiency, malignant tumours
- Active gastrointestinal bleeding
- History of upper gastrointestinal surgery
- History of drug hypersensitivity
- Use of bismuth compounds or antibiotics within the past 4 weeks, or acid-suppressing agents within the past 2 weeks
- Pregnant or lactating women
- Individuals unable or unwilling to provide informed consent
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study is a multicentre, non-inferiority randomized controlled trial to compare the efficacy and safety of 14-day vonoprazan-based dual therapy with versus quadruple therapy for the eradication of Helicobacter pylori. The primary outcome is eradication rate, and the secondary outcome includes the incidence of adverse events and compliance.
The 3 groups in the trial
- 14-day vonoprazan-amoxicillin dual therapyTreatment being tested
- 14-day vonoprazan-amoxicillin-levofloxacin-bismuth quadruple therapyExisting treatment, for comparison
- 14-day vonoprazan-amoxicillin-clarithromycin-bismuth quadruple therapyExisting treatment, for comparison
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 23 October 2026